Forming are regulator of actin cytoskeleton. They are characterized with two formin homology domains. Diaphanous-related formin (DRF) is isolated as a subfamily because they have two specific domains such as CBD(GTPase binding domain) and DAD(Diaphanous-autoregulatory domain). DRF is required for a growing number of biological progresses, such as cell adhesion and motility,cytokinesis, morphogenesis, cell polarity and the transcriptional activation of serum response factor. They are closely invovled in cell signal transduction of Rho/Rock, so they play an important role in actin cytoskeleton rearrangements and the process of neoplasm invasion and matastasis. DRF should be studied further, for it will be helpful for deep revealing the mechanism of neoplasm invasion and matastasis, and may be an important basis of potential targets for clinic practice.

Based on the characteristics of the scientific research for the hospitM in new period,this paper studied on the construction of management regulations for the laboratory animal center combining the developing condition of the laboratory animal in the hospital.

Objective:To analyze the clinical efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced NSCLC.Methods:We collected 23 cases of NSCLC advanced patients, who were treated in the affiliated Cancer Hospital of Guangzhou Medical University from January 2015 to March 2020. And these 23 cases of patients with first-generation EGFR-TKIs resistance were treated with the third-generation EGFR-TKI drugs. We analyzed their clinicopathological characteristics, studied their therapeutic effects, and followed up their progression-free survival (PFS).Results:It is showed that 16 of 23 cases (69.56%) were got local progression and 7 of 23 cases (31.43%) were found with systemic progression. Briefly, the median PFS of the 23 patients was 17.5 months. A total of 7 cases occurred rashes after taking EGFR-TKI, and 3 cases got abnormal liver function. Fortunately, they were all improved after symptomatic treatments. Additionally, no bone marrow suppression (granulocytes, neutropenia, thrombocytopenia, anemia) and digestive tract reactions (nausea, vomiting, diarrhea) were occurred in 23 cases of NSCLC patients. The mental and physical improvement of EGFR-TKI in the third generation of 19 patients was more obvious than that in the first generation of EGFR-TKI. Among them, 15 cases showed more obvious lesion shrinkage after third-generation EGFR-TKI treatment. 4 patients with GGO had cleaner disappearance than that of the first-generation EGFR-TKI.Conclusions:Compared with traditional chemotherapy, the first-generation EGFR-TKI resistance treatment with three-generation EGFR-TKI treatment has better efficacy with reduced toxic and side effects, and significantly improved the life quality of advanced NSCLC patients.